Acesion Pharma unveils positive pre-clinical data for AP31969
Acesion Pharma has announced positive data from pre-clinical studies with AP31969, developed for chronic oral maintenance treatment to prevent atrial fibrillation (AF) recurrence.
Source: biopharma-reporter.com